A Phase I Study of TTI-621 Immunotherapy in Patients with Persistent or Recurrent Blood Cancers


Full Title

Clinical Protocol TTI-621-01: A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects with Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors


The purpose of this study is to assess the safety and preliminary effectiveness of the investigational drug TTI-621in patients with blood cancers that have continued to grow or came back despite prior treatment. TTI-621blocks a protein on cancer cells called CD47. Cancer cells use CD47 to protect themselves from the immune system. It is hoped that by blocking CD47, the immune system will be better able to recognize and destroy cancer cells.

TTI-621is given intravenously (by vein).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have non-Hodgkin lymphoma (except cutaneous T-cell lymphoma), Hodgkin lymphoma, multiple myeloma, chronic lymphocytic leukemia, acute myeloid leukemia, or myelodysplastic syndrome that has continued to grow or came back despite prior treatment.
  • At least 2 weeks must pass between the completion of previous therapies and entry into the study.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Alexander Lesokhin at 212-639-3069.